USTR-2010-0037
UNITED STATES TRADE REPRESENTATIVE

IN THE MATTER OF
2011 SPECIAL 301 REVIEW:
IDENTIFICATION OF COUNTRIES UNDER SECTION 182 OF THE TRADE ACT OF 1974

SUBMISSION OF GLOBAL HEALTH ORGANIZATIONS:

Alianza LAC-Global por el Acceso a los Medicamentos
Colombia

All India Drug Action Network
India

Center for Policy Analysis on Trade and Health
United States

Fundación Misió Salud
Colombia

Health Action International - Latin America and the Caribbean
Peru

Intellectual Property Justice
United States

Health Global Access Project (GAP)
United States

LOCOST
India

Oxfam America
United States

Sean Fiil-Flynn (Counsel of Record)
Mike Palmedo
Meredith Jacob
Cameron C. Chong
American University Washington College of Law
4801 Massachusetts Ave NW
Washington DC 20016
(202)274-4157

February 15, 2011
SUMMARY ........................................................................................................................................... 1
ARGUMENT ........................................................................................................................................ 3

I. USING SPECIAL 301 TO PROMOTE RESTRICTIONS ON PUBLIC HEALTH FLEXIBILITIES IN TRIPS VIOLATES INTERNATIONAL LAW AND ADMINISTRATION POLICY .......................................................................................... 3
   A. TRIPS Flexibilities are Integral to the TRIPS Agreement .......................................................... 3
   B. Past USTR Efforts to Restrict TRIPS Flexibilities Violated the Doha Declaration ................... 5
   C. PEPFAR Depends on Access to Generic Medicines ................................................................... 9
   D. Threatening Trade Sanctions through Special 301 Violates the WTO Dispute Settlement Understanding 10
II. REVIEW OF THE 2010 REPORT: A CONTINUED FAILURE TO RESPECT ACCESS TO MEDICINES ................................................................. 12
   A. The 2010 Report Fails to Fully Endorse and Honor the WTO Doha Declaration .................... 12
   B. The 2010 ReportIncludes Numerous Listings of Countries for Taking Advantage of TRIPS Flexibilities that Promote Access to Medicines ........................................................................ 13
      1. Data Exclusivity ...................................................................................................................... 13
      2. Restrictions on Compulsory Licensing .................................................................................. 18
      3. Patent Extensions .................................................................................................................. 19
      4. Patenability Criteria .............................................................................................................. 20
      5. Disclosure of Origin Requirements ...................................................................................... 21
      6. Vague Definitions of “Counterfeit” Pharmaceuticals .............................................................. 21
      8. Enforcement Requirements ................................................................................................. 23
   C. The 2010 Report Fails to Promote Best Practices in Innovation Policy ...................................... 24
   D. USTR Should Continue to Improve Transparency and Due Process Within Special 301 .............. 26
      1. Adequate Notice and Right of Reply ..................................................................................... 27
      2. Neutral Arbiter and Right of Appeal ..................................................................................... 27
      3. Objective and Transparent Standards ................................................................................... 28
      4. Public Interest Representation ............................................................................................. 28
      5. Allowing Testimony Delivered via Teleconferencing or Web Conferencing ......................... 29
      6. Inclusion of Relevant U.S. Government Agencies ................................................................. 29

SUMMARY
INTRODUCTORY STATEMENT

We commend USTR for taking the steps it has to open the Special 301 process to greater participation by public interest organizations and targeted governments. We also commend USTR for taking steps to bring the Special 301 Report into greater alignment with commitments the United States has made under the Doha Declaration on TRIPS and Public Health to promote greater access to affordable medicines in developing countries. We call on USTR to fully abide by the Doha Declaration on TRIPS and Public Health and end the use of Special 301 to promote TRIPS plus policies that endanger access to medicines in developing countries.
USTR’s past policy of using the Special 301 Report to promote TRIPS-plus restrictions on access to medicines violates U.S. commitments under the 2001 WTO Doha Declaration on the TRIPS Agreement and Public Health, the multilateral commitments in the World Trade Organization and World Health Organization, ethical guidelines of the Declaration of Helsinki, express Congressional policy, Obama campaign pledges, the best interests of the PEPFAR program, the interests of global health, and international human rights obligations.

We call on the Administration to extend the policy guidelines of President Clinton’s Executive Order 13155 to all developing countries. Specifically, it should be the policy of the United States that:

(a) The United States shall not seek -- through Special 301, negotiation, sanction, trade preference, or otherwise -- the revocation or revision of any intellectual property or pharmaceutical market regulation of any developing country that

(1) promotes access to affordable pharmaceuticals or medical technologies; and
(2) provides adequate and effective intellectual property protection as defined by the minimum standards in the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights.

Furthermore, the U.S. government could use the Special 301 process to pursue pro-innovation policies that match existing and new commitments in the United States. For example, it could encourage our trading partners to invest more in public sector R&D, including open source projects, and could highlight best practices to promote access to knowledge, such as the NIH policies to provide open access to published scholarly and scientific research when the research benefited from government funding.

At a minimum, the Special 301 program needs serious procedural reforms to provide the full and fair adjudicative process needed to ascertain relevant facts and fairly interpret and implement the statutory requirements. Full administrative justice norms should be afforded during the adjudicative process, including adequate notice and a right of reply, a neutral
arbitrator and right of appeal, objective and transparent standards and interpretations of law, and a public interest representation program.

Finally, we ask that USTR provide a communication link for parties interested in testifying at the March 2 Special 301 Hearing, but unable to travel to Washington, D.C.

ARGUMENT

I. USING SPECIAL 301 TO PROMOTE RESTRICTIONS ON PUBLIC HEALTH FLEXIBILITIES IN TRIPS VIOLATES INTERNATIONAL LAW AND ADMINISTRATION POLICY

A. TRIPS Flexibilities are Integral to the TRIPS Agreement

During the negotiation of the TRIPS agreement, concerns about its impact on access to medicines were a primary issue for many countries. Pharmaceutical patents grant monopoly rights to patent holders, allowing them to charge much higher prices than would be possible in a competitive environment. That effect is justified by the assertion that a portion of those excess profits would be directed toward research and development of new medicines. But increased prices also limit access to affordable medications. This is most pronounced in developing countries with high income inequality where monopolies on medicines predictably lead to profit maximizing pricing that will exclude the great majority from access, while providing miniscule incentive for future innovation.¹

In recognition of the unbalanced costs and benefits of intellectual property protection, particularly with respect to medicines in poorer countries, it is commonly accepted by the world’s leading public health organizations and development economists that intellectual

¹ Sean Flynn, Aidan Hollis & Mike Palmedo, An Economic Justification for Open Access to Essential Medicine Patents in Developing Countries, 37 J.L. Med. & Ethics 184 (2009).
property rules for medicines should differ among countries. Similarly, a one-size-fits-all intellectual property norm was emphatically rejected in the WTO negotiations. The TRIPS agreement contains minimum standards for patents and other forms of intellectual property for all countries. But the Agreement contains important flexibilities that can and should be used to tailor the contours of intellectual property protection to public health and other public interests.

Primary among the TRIPS flexibilities supporting access to medicines:

- **Compulsory licenses.** TRIPS protects the authority to grant a compulsory license or government use order for any patented product for any reason, subject only to the procedural and adequate compensation requirements of Art. 31;
- **Scope of patentability.** Countries have freedom to define the scope of patentable subject matter through legislative or policy definitions of the criteria that inventions be “new,” “involve an inventive step” and are “capable of industrial application,” (Art. 27), including by rejecting patents for minor improvements or new uses of known products;
- **Parallel importation.** Countries may define “exhaustion of rights” for intellectual property to allow parallel importation of IP-protected products between countries;
- **20 year patents.** Countries may limit patents to 20 years (Art. 28), with no extensions for new uses of existing products or for problems of regulatory delay;
- **Freedom from linkage.** Countries are not required to implement any “linkage” between the drug registration and assertions of patent protection, which can

---


1. Members may, in formulating or amending their laws and regulations, adopt measures necessary to protect public health and nutrition, and to promote the public interest in sectors of vital importance to their socio-economic and technological development, provided that such measures are consistent with the provisions of this Agreement.
2. Appropriate measures, provided that they are consistent with the provisions of this Agreement, may be needed to prevent the abuse of intellectual property rights by right holders or the resort to practices which unreasonably restrain trade or adversely affect the international transfer of technology.
permit improper use of the registration system by patent holders to delay legitimate generic entry into a market;

- **Flexible data protection.** Countries are not required to adopt U.S. or EU-style “data exclusivity” as the form of protection for undisclosed information under Art. 39.3, thereby avoiding the grant of marketing monopolies for medicines that operate independently of patent status;

- **Freedom of regulation.** Freedom to use other regulatory systems, including competition policies, reimbursement formularies and price regulations to restrain excessive pricing by patent holders, in particular “to protect public health and nutrition, and to promote the public interest in sectors of vital importance to their socio-economic and technological development.” (Art. 8).

B. Past USTR Efforts to Restrict TRIPS Flexibilities Violated the Doha Declaration

Past trade agreements and listings in Special 301 have attempted to limit each TRIPS flexibility identified above.\(^4\) USTR has pressed countries to limit grounds for compulsory licenses, restrict freedom to define the scope of patentability, prohibit parallel importation, extend patents beyond 20 years, implement “linkage” between drug registration and assertions of patent protection, adopt U.S. or EU-style “data exclusivity” rules, and do away with evidence-based formularies and other price and competition restrictions on pharmaceutical monopoly power.

TRIPS-plus pressure by USTR on access to medicines has been widely condemned by domestic and international experts and officials.

- In response to global outrage at U.S. use of Special 301 and other pressure on countries to restrict compulsory licenses and other TRIPS flexibilities, President

---

Clinton banned TRIPS-plus pressure in Africa in Executive Order 13155 and WTO member states unanimously adopted the 2001 Doha Declaration, affirming “the right of WTO Members to use, to the full, the provisions in the TRIPS Agreement, which provide flexibility [to promote access to medicines for all].”

- The World Health Organization has urged developing countries to “be cautious about enacting legislation that is more stringent than the TRIPS requirements,” and admonished: “Bilateral trade agreements should not seek to incorporate TRIPS-plus protection in ways that may reduce access to medicines in developing countries.”

- In 2008, after more than 2 years of negotiation, all the WHO Member States, including the U.S., adopted by consensus the historic resolution WHA 61.21 containing a Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property. Through the Plan of Action, the U.S. agreed “to take into account in trade agreements the flexibilities contained in the Agreement on Trade-Related Aspects of Intellectual Property Rights and including those recognized by the Declaration on the TRIPS Agreement and Public Health adopted by the WTO Ministerial Conference and the WTO decision of 30 August 2003.”

- Congress has shown support for the Doha Declaration and Members have frequently criticized TRIPS-plus trade pressure on pharmaceuticals.
  - The Kennedy Amendment to the 2002 Trade Promotion Authority legislation was intended to block TRIPS-plus trade pressure by requiring that trade authority respect the Doha Declaration.
  - In June 2005, the Committee on Government Reform reported that promoting TRIPS-plus provisions on pharmaceuticals are “[c]ontrary to

---

5 Doha Declaration, para. 4 (emphasis added).
6 See WHO, Globalization, TRIPS and Access to Pharmaceuticals, WHO Doc WHO/EDM/2001.2 (Mar. 2001) at 4-5 (stating “Poorer populations in developing countries should not be expected to pay the same price as do the wealthy for newer essential drugs. TRIPS-compliant mechanisms can be used to lower drug prices.”). 
the principles of the Doha Declaration” because they “will significantly impede the ability of developing countries to obtain access to inexpensive, lifesaving medications.”

- On May 10, 2007, a bipartisan group of congressional leaders and the Bush Administration agreed to a “New Trade Policy for America,” which limited pending trade agreement provisions on data exclusivity, and excluded requirements for linkage and patent extensions.
- The inclusion of Thailand and Brazil on the 2007 Special 301 watch lists for using compulsory licensing was criticized by dozens of Members of Congress for sending “a troubling message” to the “whole world . . . that the exercise of recognized public health flexibilities in trade obligations is frowned on by the United States.”
- Members of Congress have urged that in Special 301 “countries should not be cited for the use of compulsory licenses or other flexibilities in accordance with international trade rules.”
- Soon after the release of the 2007 Special 301 Report, resolutions were introduced in the Senate and House calling on the USTR to “honor” the Doha Declaration’s affirmation of the rights “to use ‘to the full' the flexibilities” in TRIPS, and “not place countries on the ‘Special 301’ Priority Watch List . . . for exercising the flexibilities on public health provided for in the TRIPS Agreement.”

- The UN Special Rapporteur on the Right to Health has issued a report declaring that TRIPS-plus trade pressure on developing countries by wealthy countries may constitute a human rights violation.

---

10 Waxman Report at ii.
14 The Special Rapporteur, Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health, U.N. doc. A/HRC/11/12 (Mar. 31, 2009). The report finds that “[d]eveloped States also have a responsibility to take steps towards the full realization of the right to
In 2009, 26 global health organizations adopted a Platform on Trade-Related Intellectual Property and Health Issues, including the principle that the administration should “[f]orbid the use of threats and punitive actions, such as listing in the Special 301 Watch List and/or withdrawal of Generalized System of Preferences benefits, in response to a country’s use of TRIPS safeguards and flexibilities or refusal to adopt TRIPS-plus measures.”

Promoting access to affordable medicines through use of TRIPS flexibilities is part of President Obama’s global health platform. President-elect Barack Obama and Vice President-elect Joe Biden pledged to “increase access to affordable drugs” in developing countries, including “access to safe, affordable generic drugs to treat HIV/AIDS.” As President-elect, Obama released a platform promising to “break the stranglehold that a few big drug and insurance companies have on these life-saving drugs,” and pledging support for “the rights of sovereign nations to access quality-assured, low-cost generic medication to meet their pressing health through international assistance and cooperation,” and admonished that “[f]rom a right to health perspective, developing countries and LDCs should be enabled to use TRIPS flexibilities.” The report specifically states that all developing countries “should incorporate the flexibility to: (a) Make full use of the transition periods; (b) Define the criteria of patentability; (c) Issue compulsory licences and provide for government use; (d) Adopt the international exhaustion principle, to facilitate parallel importation; (e) Create limited exceptions to patent rights; (f) Allow for opposition and revocation procedures. In addition, countries need to have strong pro-competitive measures to limit abuse of the patent system.”

15 U.S. Civil Society Platform on Trade-Related Intellectual Property and Access to Medicines Issues (2009) available at http://www.essentialaction.org/access/uploads/IP-MedsPlatformMay2009.pdf. The signatories included: ACT UP/New York; ACT UP/Philadelphia; ActionAid International USA; Africa Action; African Services Committee; American Medical Student Association (AMSA); American Public Health Association (APHA) Trade and Health Forum; American University, Washington College of Law, Program on Information Justice and Intellectual Property (PIJIP); Center for Policy Analysis on Trade and Health (CPATH) Essential Action; Forum on Democracy & Trade; Global AIDS Alliance; Health GAP (Global Access Project) Interfaith Center on Corporate Responsibility (ICCR); Knowledge Ecology International (KEI); Missionary Oblates of Mary Immaculate; Oxfam America; Peoples Health Movement-USA; Salud y Fármacos; Stop HIV/AIDS in India Initiative (SHAII); Student Global AIDS Campaign (SGAC); TransAfrica Forum; Treatment Action Group (TAG) Universities Allied for Essential Medicines (UAEM); The University Coalitions for Global Health (UCGH) Vermont Global Health Coalition. According to the platform, U.S. trade policy should 1) Promote availability of affordable life-saving medications and protect public health in developing countries; 2) Promote innovation to develop and distribute new, effective medicines that address essential health needs without limiting access to existing or future medical products; 3) Respect the right of all governments to regulate pharmaceutical markets and ensure equitable access; 4) Promote transparency and integrate public health interests into trade policy-making.
C. PEPFAR Depends on Access to Generic Medicines

The U.S. is a major purchaser of antiretroviral and other medicines for people living with HIV/AIDS through the President’s Emergency Plan for AIDS Relief (PEPFAR). President Bush, in announcing his PEPFAR initiative, directly referenced the low-cost of generic medicines as enabling PEPFAR’s scale up. In FY 2008 some 89% of all antiretroviral drugs delivered by PEPFAR were generics, saving the program $215 million. To obtain the greatest value for the money, to ensure sustainability of treatment and to treat the greatest number of patients at the lowest cost, U.S. trade policy must promote access to affordable medicines through the use of TRIPS flexibilities in developing countries.

The World Health Organization has recommended improved treatments for HIV/AIDS in resource-poor settings. These new norms for the treatment of HIV/AIDS include the use of more effective medicines with reduced toxicities, but they tend to be considerably more expensive. As U.S. Global AIDS Coordinator Eric Goosby (and others) recently wrote in the Journal of the American Medical Association:

Several developments threaten additional reductions in the cost of

19 Charles Holmes et al., Use of Generic Antiretroviral Agents and Cost Savings in PEPFAR Treatment Programs, 304(3) JAMA 313 (July 21, 2010).
ARVs in the short-to-medium term … [including] the accelerating migration away from stavudine-based regimens, for which many inexpensive generic [fixed dose combinations] exist and for which prices have decreased substantially. The cost of tenofovir and zidovudine, 2 of the drugs increasingly recommended in international and country guidelines, remain at least 2 times that of stavudine.21

Furthermore, as people receiving PEPFAR-funded medicines remain on antiretroviral therapy, they will develop resistance to first line medicines and require more costly second line medicines.22 PEPFAR currently pays $402 per patient per year for treatment with first line therapy, but $942 per patient per year for treatment with second line therapy.23 Other funding sources – either recipient country governments or nonprofit groups – supplement PEPFAR treatment funding, so that the total cost of first line treatment for a person in PEPFAR is $754 and the total cost for a person receiving second line treatment through PEPFAR is $1,745.24 Greater generic competition will be needed if the prices of second line ARVs are to fall.

D. Threatening Trade Sanctions through Special 301 Violates the WTO Dispute Settlement Understanding

The current use of Special 301 likely violates the WTO accord and contradicts this Administration’s policy against promoting unilateral resolution of multilateral disputes.

Enacted at a time when there was no international minimum standard for intellectual property and no effective multilateral dispute mechanism,25 Special 301 authorized a unilateral...
adjudication of trade disputes involving intellectual property. It is frequently used to unilaterally define and enforce TRIPS, as has been the case with USTR’s strained interpretation of TRIPS data protection requirements discussed below. In other circumstances it is used to sanction countries for failing to adhere to intellectual property obligations that do not exist in any trade agreement, as has been the case with the push for patent registration linkage, also discussed below. In either case, such unilateral action in the trade arena violates the multilateral dictates of the WTO.

The WTO requires that trade disputes be settled before multilateral dispute settlement panels. This requirement bans countries from using sanctions, or the “threat alone” of sanctions, to enforce norms not adjudicated through the multilateral process. Special 301’s original purpose was to threaten sanctions for non-compliance with unilaterally defined intellectual property standards. With the advent of the WTO and TRIPS, this purpose is no longer justified or legal.

---

26 The program is an extension of the Section 301 program, which responded to the lack of effective multilateral enforcement in the General Agreement on Trade Tariffs by authorizing the President (through USTR) to unilaterally impose trade sanctions for any foreign practices that “burden[] or restrict[] United States commerce.” The program did not require that the targeted practice violate any trade agreement, and countries were routinely sanctioned for policies that did not violate international standards.

27 Understanding on Rules and Procedures Governing the Settlement of Disputes, Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade Organization, Annex 2, art. 23.2, Legal Instruments – Results of the Uruguay Round vol. 31, 33 I.L.M. 81 (1994) (“Members shall not make a determination to the effect that a violation has occurred, that benefits have been nullified or impaired or that the attainment of any objective of the covered agreements has been impeded, except through recourse to dispute settlement in accordance with the rules and procedures of this understanding.”); for articulation of the MFN argument against Special 301 Reports, see Jagdish Bhagwati and Hugh T. Patrick (eds.), Aggressive Unilateralism: America's 301 Trade Policy and the World Trading System, pp. 113-14 (University of Michigan 1993).

28 Panel Report, United States – Sections 301-310 of the Trade Act of 1974, ¶ 7.89, WT/DS152/R (Dec. 22, 1999) (stating “ Members faced with a threat of unilateral action, especially when it emanates from an economically powerful Member, may in effect be forced to give in to the demands imposed by the Member exerting the threat... To put it differently, merely carrying a big stick is, in many cases, as effective a means to having one's way as actually using the stick. The threat alone of conduct prohibited by the WTO would enable the Member concerned to exert undue leverage on other Members. It would disrupt the very stability and equilibrium which multilateral dispute resolution was meant to foster and consequently establish, namely equal protection of both large and small, powerful and less powerful Members through the consistent application of a set of rules and procedures.”).
The administration should undertake a careful review of the current use of Special 301 under its WTO obligations, including expert and independent legal advice from the Justice and State Departments, and work with Congress to propose necessary changes to the program.

II. REVIEW OF THE 2010 REPORT: A CONTINUED FAILURE TO RESPECT ACCESS TO MEDICINES

Because public interest groups are required to submit their comments on the same day as the industry complaints they are often responding to, this section of the submission gives specific input on the flaws in the last Special 301 Report rather than any response to the submissions of other parties submitted this year.

A. The 2010 Report Fails to Fully Endorse and Honor the WTO Doha Declaration

Public interest groups call on the administration to reverse the past policy of opposition to the plain wording of the Doha Declaration.29 Although the 2010 Special 301 Report contains a fuller commitment to the Doha Declaration, it stops short of endorsing the key wording of the declaration that is contrary to the promotion of TRIPS-plus policies on medicines issues. We call on USTR to endorse the specific language in the Doha Declaration, reiterated in the WHO Global Strategy and Plan of Action, affirming countries’ rights to use all TRIPS flexibilities “to the full” and the key Doha Declaration principle that TRIPS “can and should” be interpreted and implemented to promote access to medicines “for all.”


Despite the policy change ushered in with the application of the 2007 New Trade Agreement for America and the change in administrations to one committed to support the Doha Declaration, the 2010 Special 301 Report continued to sanction countries for policies that promote access to affordable medications consistent with TRIPS. These and all other TRIPS-plus trade pressure on developing countries should be eliminated from the 2011 Report.

1. Data Exclusivity

The most common objection in the 2010 report related to pharmaceutical policy is a desire for “protect[ion] against unfair commercial use of undisclosed test or other data generated to obtain marketing approval of pharmaceutical products.” Numerous other countries have been listed in Special 301 reports or otherwise pressured to adopt TRIP-plus data exclusivity in recent years. In most cases the 2010 Special 301 Report fails to explain what it considers to be inadequate protection of undisclosed data. In the past, however, the Special 301 Report has been used to press a position that TRIPS Art. 39.3 requires the grant of additional monopoly periods for pharmaceuticals through “data exclusivity.” This minority viewpoint appears to motivate the 2010 report as well. This position is unsupported by the text or negotiating history of the TRIPS

30 United States Trade Representative, 2010 Special 301 Report (Apr. 30, 2010) at 22 [hereinafter 2010 Report]. Nine of the eleven countries on the Priority Watch List is targeted for such a complaint as are ten of the Watch List countries and Paraguay, identified as a Section 306 monitoring case. Reference to data exclusivity is also made in the Report’s section on Israel (Status Pending) wherein subject to an agreement between the US and Israel finalized on Feb. 18, 2010, Israel has committed itself to protecting pharmaceutical test data and patent term extensions. This action was lauded in the Report but its outcome has yet to be seen.
31 Guatemala is a key example. See, e.g., Ellen R. Shaffer and Joseph E. Brenner, A Trade Agreement’s Impact On Access To Generic Drugs, Health Affairs, 28, 5 (2009): w957-w968 (Aug. 2009) (describing use of Special 301 and other trade pressure for Guatemala to adopt data exclusivity); United States Trade Representative, 2003 Special 301 Report (May 1, 2003) [hereinafter 2003 Report] (listing Guatemala on the watch list after it repealed a law requiring 15 years of data exclusivity); see also separate 2010 comment submission by the Center for Policy Analysis on Trade and Health (CPATH) on repeated misuses of 301 Reports to penalize Guatemala for legal measures to provide affordable medicines.
Agreement, is a clear violation of the Doha Agreement, is a violation of the sovereignty of other nations, and is bad global health policy.

The issue of access to pharmaceutical test data arises because of requirements that manufacturers must prove the safety, efficacy and quality of medicines through clinical trials or other data. When a generic manufacturer subsequently attempts to obtain marketing approval for a therapeutically equivalent medicine, it is normally required to prove only bioequivalence to the already approved drug and Good Manufacturing Practice. In this way, the generic firm relies on the original safety and efficacy data that the regulator has already reviewed and approved, rather than repeating animal and human trials, which would be prohibitively costly, time-consuming and ethically troublesome.\(^{32}\)

Data exclusivity can have particularly harmful effects in developing countries. In many developing countries, drug companies lack patents because they were never sought or granted. In such circumstances, data exclusivity grants a marketing monopoly in the absence of patent protection. Another problem is that companies often register their products in developing countries very late, focusing instead on the wealthy markets. When this is the case, data exclusivity can extend monopoly periods past the point at which the medicine is subject to full competition in the U.S.\(^{33}\)

\(^{32}\) See World Medical Association, Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects, 18th WMA General Assem. Art. 20 (Jun. 1964) (stating “[p]hysicians may not participate in a research study involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians must immediately stop a study when the risks are found to outweigh the potential benefits or when there is conclusive proof of positive and beneficial results.” Repetition of clinical trials on human subjects would therefore violate international ethical standards for clinical trials, which forbid doctors to continue experiments on humans “when there is conclusive proof of positive and beneficial results.”); see also Global Strategy and Plan of Action (committing to “[p]romote ethical principles for clinical trials involving human beings as a requirement of registration of medicines and health-related technologies, with reference to the Declaration of Helsinki, and other appropriate texts, on ethical principles for medical research involving human subjects, including good clinical practice guidelines.”).

\(^{33}\) Waxman report at 7.
The TRIPS agreement requires that certain pharmaceutical test data submitted to registration authorities be protected from “unfair commercial use.”\textsuperscript{34} Article 39.3’s literal scope is relatively narrow.\textsuperscript{35} Importantly, countries have great leeway in defining what use or reliance on test data may be an “unfair commercial use.” The WHO has advised that most traditional uses of registration data to approve generic medicines do not need to be defined by states as an unfair commercial use of that data.\textsuperscript{36}

The WHO’s interpretation is consistent with the writings of the leading legal scholars on the TRIPS agreement and public health.\textsuperscript{37} It is also consistent with the Doha Declaration’s mandate that the TRIPS agreement can and should be interpreted to promote access to medicines.

The practice of providing a form of exclusivity for pharmaceutical test data originates with the Hatch Waxman Act in the U.S. The primary effect of that Act was to implement a fast

\textsuperscript{34} TRIPS Art. 39.3 specifically states:

\begin{quote}
Members, when requiring as a condition of approving the marketing of pharmaceutical or of agricultural chemical products which utilize new chemical entities, the submission of undisclosed test or other data, the origination of which involves a considerable effort, shall protect such data against unfair commercial use.
\end{quote}

\textsuperscript{35} Test data must be protected only if: (1) national authorities require its submission; (2) it is undisclosed, not already public, (as many clinical trial results in the U.S. are by virtue of state and local clinical trial registry laws); and (3) it concerns a new chemical entity, i.e. it the undisclosed data is “the result of significant investment,” proof which could be required.


track for generic approval through reliance on past submitted clinical trial data by originator. But the Act included a political compromise by prohibiting such reliance in the first five years after the registration data is filed. In the EU, data exclusivity periods were later enacted that can run as long as 10 years.\textsuperscript{38} These periods operate independently of any period of patent exclusivity, and in the EU have been interpreted to be impervious to compulsory licensing, even in a health emergency.\textsuperscript{39}

Most countries in the world do not follow exclusivity rules, but rather allow generic companies to register products and come on the market through bio-equivalency demonstration at any point.\textsuperscript{40} In such countries, the only marketing monopoly companies receive is through the patent system rather than the registration system. As the WHO has explained, this is the pro-access to medicines approach:

This approach emphasizes that the registration of products should not erect barriers to otherwise legitimate competition. It holds, instead, that the registration system should promote price competition and access to more affordable medicines.\textsuperscript{41}

Contrary to the policies of a majority of countries, USTR has adopted a radical legal interpretation of TRIPS that Article 39.3 requires data exclusivity. During the TRIPS negotiating process, the U.S. proposed language for Article 39 requiring that pharmaceutical test data be

\textsuperscript{38} In the U.S., the data originator obtains five years of data exclusivity for a new chemical entity and an additional three years for marketing approvals of new uses, new formulations, or new dosages that require the submission of new clinical trial data. In Europe, the data originator obtains ten years of data exclusivity and can obtain an additional, one-time-only one-year extension for registering a significant improvement. See e.g. Brook Baker, \textit{Ending Drug Registration Apartheid – Taming Data Exclusivity and Patent/Registration Linkage}, 34 Am. J. L. & Med. 303-344 (2008).

\textsuperscript{39} European Commission Directorate General for Enterprise and Industry, Letter from Martin Teberger, Head of Unit for Consumer Goods to the European Generic Pharmaceuticals Association (Feb. 20, 2006) available at wcl.american.edu/ pijp/go/eu02202006 (stating “[t]he European pharmaceutical legislation does not foresee any exception to the... periods of 8 year data exclusivity and 10 years marketing protection in case of emergency situation or in case a compulsory patent license has been granted by an EU Member State.”).

\textsuperscript{40} See Musungu and Oh, \textit{supra} note 39 at 65-67 (surveying countries).

\textsuperscript{41} See Correa, \textit{supra} note 38 at xi.
“reserved for the exclusive use of the registrant for a reasonable period.”\textsuperscript{42} That proposal was specifically amended out of the agreement in negotiation.\textsuperscript{43} Nevertheless, PhRMA continues to petition the USTR to force countries to implement regulations that “prevent generic producers from securing marketing approval for the same or similar product by relying, directly or indirectly on the originator’s data, without consent, during the designated period of exclusivity.”\textsuperscript{44} And USTR has adopted this position in past 301 Reports, asserting:

the TRIPS Agreement recognizes that the original applicant should be entitled to a period of exclusivity during which second-comers may not rely on the data that the innovative company has created to obtain approval for their copies of the product.\textsuperscript{45}

Elsewhere, USTR has proclaimed that “any other” interpretation of Article 39.3 “would be inconsistent with logic and the negotiating history of the provision.”\textsuperscript{46}

The USTR interpretation of 39.3 as requiring data exclusivity is frivolous and would not stand up in any neutral adjudicative forum.\textsuperscript{47} Article 39.3 provides no definition of what kind of protection against unfair commercial use must be provided. In the absence of some statutory interpretation, the USTR is obliged under international trade agreement interpretation to define the term based on local definition in sovereign implementing states. A requirement for data exclusivity was specifically considered and amended out of the text of TRIPS. The Doha Declaration, which is a subsequent agreement by the same members (including the U.S.) and

\textsuperscript{42} See Correa, supra note 38 at 53.


\textsuperscript{44} Pharmaceutical Research and Manufacturers of America (PhRMA) \textit{Special 301 Submission 2010}, 2 [hereinafter 2010 PhRMA Submission] available at http://www.regulations.gov/#!documentDetail;D=USTR-2010-0035-0007.2 (arguing that the Thai government needs to implement new data exclusivity laws specifically to prevent “early” generic medicine approval).

\textsuperscript{45} 2003 Report at 4-5.


\textsuperscript{47} See Correa, supra note 38 at 5.
therefore helps define and interpret the TRIPS terms, demands that states interpret TRIPS to promote access to medicines. In combination, these subsequent commitments by the U.S. to the promotion of access to medicines, the abandonment of data exclusivity regimes in TRIPS, and the mutual respect for national sovereignty observed by all WTO Members, lead to one legal conclusion: “Countries are not obligated under Article 39.3 to confer exclusive rights on the originator of marketing approval data.”

In the 2011 Special 301 Report, USTR should refrain from listing any country for protection of undisclosed data that complies with any reasonable interpretation of TRIPS Art. 39 (including protection limited to illegal theft of trade secrets). At minimum, no country should be listed for policies that comply with the 2007 New Trade Deal between the Congress and Bush Administration.

2. Restrictions on Compulsory Licensing

The 2010 Report also raises some concerns about compulsory licensing. Compulsory licensing is perhaps the most important flexibility in the TRIPS agreement. A compulsory license is a government-issued license to one or more competitors permitting entry in the market upon payment of adequate royalties to the patent holder. The Doha Declaration affirms the broad right of all countries to use compulsory licenses to promote access to medicines, stating that each

---

48 Id. For other criticisms of U.S. pressure for developing countries to adopt data exclusivity policies, see Letter from Members of the House Ways and Means Committee, United States House of Representatives, to Robert Zoellick, President of the World Bank (Jan. 26, 2005) available at http://www.cpath.org/sitebuildercontent/sitebuilderfiles/congressguatemalatest-data-secrecy-letter1-05.pdf. (consequences of data exclusivity provisions “are the exact opposite of those intended by the Doha Declaration”); World Health Organization’s 2006 Report of the Commission on Intellectual Property Rights, Innovation and Public Health (recommending “that developing countries should not impose restrictions for the use of, or reliance on, data from pharmaceutical development tests in ways that would exclude fair competition or impede the use of flexibilities built into the TRIPS Agreement”);

49 See Correa, supra note 38 at 41-47 (explaining that such a minimum provision would satisfy Art. 39 of TRIPS).
country “has the right to grant compulsory licenses and the freedom to determine the grounds upon which such licenses are granted.”

The 2010 Report lists both China\(^\text{50}\) and Ecuador\(^\text{51}\) as subject to observation for issues concerning compulsory licensing. As with most of the report, the USTR fails to elaborate on what particular policies or changes must be made in China and Ecuador’s respective compulsory licensing regimes, the implication being that they should bring their regimes into compliance with U.S. standards. With discussion on Ecuador, the report also raises discussion of the Doha Declaration as something to be borne in mind when revising compulsory licensing changes.\(^\text{52}\)

While this facially reflects the U.S.’s commitment to access to medicines, to request changes in compulsory licensing legislation obstructs the Declaration’s objective.

In the 2011 report, USTR should refrain from listing any country for use or authorization in law or policy of TRIPS-compliant compulsory licenses.

3. Patent Extensions

Under TRIPS, WTO members are required to grant patents for a period of 20 years from the time the patent is filed. This period is three years longer than the period for which the U.S. previously granted patents, and takes into account the known delays in regulatory processes. The 2007 New Trade Deal for America removed the requirement for patent extensions in then-pending FTAs. Yet USTR has continued to use Special 301 to pressure countries to adopt patent extensions.\(^\text{53}\) In the 2011 Report, USTR should refrain from singling out any country to promote TRIPS-plus patent extensions.

---

\(^{50}\) See 2010 Report at 22.
\(^{51}\) See Id. at 31.
\(^{52}\) See Id.
\(^{53}\) See 2010 Report (requesting Israel “amend its laws to increase the effective patent term extension given to pharmaceutical products to compensate for delays in the regulatory approval process.”)
4. Patentability Criteria

The 2010 Report calls upon India and the Philippines to revise their current patent laws which “prohibit[] patents on certain chemical formulas absent a showing of increased efficacy.”\(^{54}\) This efficacy standard, while more stringent than the U.S.’s secondary use standard for new patent issuance, is still permissible under TRIPS.

TRIPS does not require the issuance of second-use patents. It requires patents on new products and processes, but not on new uses.\(^{55}\) Second use patents are one method by which pharmaceutical companies can “evergreen” their patent – i.e. by filing a patent for a second use of an existing medicine close to the expiration date of the first patent. TRIPS leaves it up to countries to define their criteria for what products are sufficiently “new” and involve an “inventive step” so as to qualify for a patent monopoly.

The 2010 Report notes “concern” that Brazil’s sanitary regulatory agency reviews certain patent applications for patents in the health field. Involvement of health officials in the patenting process is a best practice that should be emulated, not criticized. Health officials may be able to contribute to the analysis of whether a claimed new product is actually new and useful, which lies at the heart of patent analysis. Criticism of such novel institutional arrangements has no place in the Special 301 process.

The 2011 Special 301 Report should halt listing of countries for scope of patentability or patent examination process issues that are not regulated by TRIPS.

---

\(^{54}\) See 2010 Report at 26.
5. Disclosure of Origin Requirements

The 2010 Report entry on China lists objections to China’s disclosure of origin requirements for patent applications. Disclosure of origin provisions are one way to comply with the Convention on Biologic Diversity’s requirement that countries promote equitable benefit sharing in their intellectual property laws. Such requirements are not prohibited by TRIPS and they may promote access to medicines by dissuading the patenting of known substances. In the 2010 Special 301 Report, no country should be listed for TRIPS-compliant disclosure of origin requirements in patent statutes.

6. Vague Definitions of “Counterfeit” Pharmaceuticals

The 2010 Report lists concerns about “counterfeit” pharmaceuticals in many of the countries on both the Priority and Watch List. However, it is unclear what definition of “counterfeit” is being used. It may be difficult to satisfy requests for enhanced enforcement against counterfeits, or to tailor appropriate enforcement policies, without a clear definition. Intellectual property is also a poor framework for addressing the broader problems commonly understood as medical counterfeiting. Further, vague or broad use of the term counterfeit can wrongly taint generic medicines with the image of criminality.

Under TRIPS, “counterfeit” has a particular meaning, referring to a product “bearing without authorization a trademark which is identical [or cannot be distinguished] to the trademark validly registered.”\textsuperscript{56} Cases of alleged infringement involving registered generics and relatively similar marks, or other intellectual property disputes which may sometimes implicate

\textsuperscript{56} TRIPS Art 51, Footnote 14. “For the purposes of this Agreement: (a) ‘counterfeit trademark goods’ shall mean any goods, including packaging, bearing without authorization a trademark which is identical to the trademark validly registered in respect of such goods, or which cannot be distinguished in its essential aspects from such a trademark, and which thereby infringes the rights of the owner of the trademark in question under the law of the country of importation;
generics, are generally quite different from trademark counterfeiting, and merit very different enforcement practices. Nevertheless the use of the term “counterfeit” in the 2010 Report seems to refer broadly to unauthorized, infringing goods.

The 2010 Report calls for enhanced anti-counterfeiting enforcement practices and more stringent civil and criminal punishments for counterfeit products. Yet, without a clear definition of “counterfeit” it is difficult to measure progress. Vague standards could also lead to enforcement activities inappropriate to the contexts of civil infringement and generic medicines.

In all references to piracy or “counterfeiting,” the 2011 Report should ensure that the U.S. position respects the legitimacy of generic medicines and clearly distinguishes generic equivalents from actual trademark counterfeits.


Sometimes, it is impossible to tell from the 2010 report what is being complained about at all. The section on Algeria concerning patents simply says “Industry continues to raise concerns over the weak protection of patents in Algeria.” The section on Jamaica says that USTR “urges the government of Jamaica to reform its patent law in accordance with international standards for patent protection.”

In the 2011 Report, USTR should identify with specificity the provisions it opposes so that more informed response can be made to its allegations. Specifically, with criticisms that attack the general patent and pharmaceutical regimes, it is imperative to give specific examples and suggestions. However, in cases of criticism that involve the invocation of TRIPS-compliant flexibilities, such action must be avoided in future reports.

58 Report at 24
59 Report at 33.
8. Enforcement Requirements

In several instances in the 2010 Report, USTR presses countries to adopt TRIPS-plus intellectual property enforcement procedures that could limit access to medicines. There are at least twenty-one countries in the 2010 Report cited for needing to implement tougher criminal or ‘deterrent’ penalties for counterfeit-related issues and at least nine countries cited for needing better border control mechanisms.

For instance, the passage for Indonesia reads: “Concerns remain over weaknesses in the IPR enforcement system, including an unreliable judicial system for IPR cases, a low number of criminal prosecutions, and non-deterrent penalties.”

There are also many vague references to toughening civil penalties. In Argentina, for example, the report cites problems in the Argentinean civil process, “including ineffective civil damages…and delays in the adjudication of IPR infringement cases.” The report does not elaborate any further than this statement in describing what problems exist or what solutions are proposed. Based on this ambiguity and lack of information, it is impossible to respond to the comment with an informed response.

There are also problematic passages throughout the Report about the need to give border officials (and others) the ability to instigate raids and confiscate suspected infringing products. Examples include the passages for Canada, Bolivia, Brazil, Kuwait, Tajikistan, Turkmenistan, Ukraine, and Uzbekistan. Seizures of legitimate medicines by border officials have become a massive problem for access to medicines around the globe, particularly through the so-called “Dutch seizure” cases in Europe. The U.S. should not be encouraging border officials to

---

60 See 2010 report at 27.
61 Id. at 24.
62 Since late 2008, customs officials in the Netherlands, Germany and France have seized at least 20 shipments of legitimate generic medicines. Of the shipments, 19 were legally manufactured and exported from India and intended
confiscate products that allegedly violate patents. Patent violations cannot be identified by sight by border officials or police. The reason we enforce patents through complex civil proceedings is that such proceedings are necessary to avoid wrongful confiscations. Further, as mentioned above, there remains an unclear definition of “counterfeit” for pharmaceutical purposes. As the U.S. definition of counterfeit seemingly extends to generic and substandard medicines, it is still unreasonable to give border examiners the authority to make decisions best left to health professionals. For medicines, wrongful confiscations harm more than economies (which itself threatens social welfare), it directly threatens the lives of people who depend on uninterrupted supplies of the medicines they need.63

C. The 2010 Report Fails to Promote Best Practices in Innovation Policy

In the 2010 report, the USTR included a section on “Supporting Pharmaceutical and Medical Device Innovation through Improved Market Access” that promotes only one narrow pro-innovation policy: convincing other countries to abandon regulatory and reimbursement programs that may delay market approval and restrain the high cost of patented prescription drugs.

USTR’s continued advocacy of higher patent protection as the only and best way to serve the global public interest in research and development for new medicines is at odds with the evidence. Exclusive marketing rights have not promoted research and development for diseases for developing countries where they could be legally imported. Patents did not exist on the medicines in either the country of origin or destination. These shipments were seized as a result of national implementation of an EU regulation that empowers border officials to classify and seize medicines as counterfeits if the customs official determines (often at the direction of pharmaceutical companies) that the medicines violate territorial patents of the relevant EU country. The IP standards of the EU countries have been applied to medicines in-transit even though these medicines are not intended for domestic consumption in the EU. Medicines that were seized included a cardiovascular disease medicine (Losartan) intended for Brazil, and a key anti-retroviral medicine, (Abacavir), purchased by the Clinton Foundation and intended for Nigeria. Without modifying or eliminating the EU regulation (or worse, expanding the regulation through new trade agreements), medicines supplied through U.S. foreign assistance programs - such as PEPFAR – could be similarly affected.

63 In the case of AIDS and other illnesses, an interruption in supply of medicines can lead to drug resistance – which harms not only the patient but the greater society effort to combat the disease.
and conditions that primarily concern poor people living in developing countries. As noted by the 2006 WHO report by the Commission on Intellectual Property Rights, Innovation and Health (CIPIH):

Intellectual property rights are important, but as a means not an end. How relevant they are in the promotion of the needed innovation depends on context and circumstance. We know they are considered a necessary incentive in developed countries where there is both a good technological and scientific infrastructure and a supporting market for new health-care products. But they can do little to stimulate innovation in the absence of a profitable market for the products of innovation, a situation which can clearly apply in the case of products principally for use in developing country markets.

There are steps the Administration could take to encourage global policies that would help global innovation for new medicines:

- Promote a rational innovation policy, including encouragement of countries to fully implement the World Health Assembly resolution 61.21, which contains a Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property. This includes supporting the WHO in its mandate to implement the entire policy agenda, as well as sufficient financial and human resources to carry it out.

- Recognize and encourage the use of diverse mechanisms that separate and de-link research and development (R&D) incentives from prices, for example through the use of innovation inducement prizes that reward innovations that improve health outcomes and permit open competition for products.

- Promote licensing of all publicly funded biomedical R&D to the developing world, for example by licensing to the UNITAID patent pool publicly-funded IP held by NIH and Universities, and by supporting similar initiatives addressing other health needs, to ensure affordable upstream and downstream access to medical technologies relevant to health needs of developing countries.

---

64 See Margaret Kyle and Anita McGahan, Investments in Pharmaceuticals Before and After TRIPS, NBER Working Paper 15468, available at http://www.nber.org/papers/w15468 (finding that “R&D effort is not associated with the implementation of TRIPS in lower income countries”).
• Organize a series of public events where a diverse range of stakeholders can present their proposals. Discussions should include innovation inducement prizes that reward improvements in health outcomes and require open licensing, the use of health-related patent pools, and proposed elements of a WHO biomedical R&D treaty.

• Encourage governments to provide open access to government funded medical research, such as is now required by the NIH Public Access Policy.

• The Special 301 report could be a means of highlighting cases where governments are meeting their R&D commitments, as recommended by the WHO CIPIH Report. ⁶⁵

D. USTR Should Continue to Improve Transparency and Due Process Within Special 301

The public interest community appreciates the strides USTR made last year to hold an open public hearing on the Special 301 report for the first time ever. In part out of this appreciation, the public interest community made great efforts to participate in this process despite none of the organizations receiving any funding specifically for this purpose. In the future, however, much more lasting structural improvements to the 301 process are needed.

USTR claims to review the IP policies of a huge number of countries every year. Yet, USTR has few dedicated staff to this effort, and lacks the necessary legal, economic, and other experts to independently research and analyze the world’s intellectual property policies and their economic effect on US trade interests. The agency therefore relies on facts to emerge from an administrative fact finding process.

⁶⁵ See 2006 CIPIH Report at 47 (stating in recommendation 2.1 that “[g]overnments of developed countries should reflect adequately this objective in their research policies. In particular, they should seek to define explicit strategies for R&D and devote a growing proportion of their total health R&D funding to the health needs of developing countries.”).
The Administration has great discretion to decide what procedures to follow in the Special 301 process. It should adopt procedures that best enable it to find truthful facts relevant to the statutory determinations it is required to make.

1. Adequate Notice and Right of Reply

The Special 301 process needs to be reformed to reflect that it is in fact an adversarial process. For the great majority of its operation, there has been absolutely no right of reply or specific notice to the accused. Industry complaints and country and other replies have been literally due on the same day. The process made a small reform in 2008 by allowing a short reply window for foreign countries. Organizations in support of foreign countries do not receive the same reply period even when their purpose is also to reply to industry complaints. Thus, this submission is responding entirely to the 2010 report rather than 2011 complaints.

In the future, the 301 process should be reformed to afford a full and reasonable reply period to foreign countries and organizations supporting them. Industry submissions should be treated as complaints and should be required to label themselves as such. Responses to the complaints from countries or other organizations challenging assertions by complainants should be given more time to reply, as is the case with court proceedings or adversarial administrative processes. There should also be a period where such parties can comment on a draft of the Report before it is finalized, as is common in many regulatory review processes.

2. Neutral Arbiter and Right of Appeal

One of the hallmarks of a just and fair administrative process is an avenue for appealing questions of law, policy and erroneous findings of fact to an independent authority. Indeed, this
procedural protection is being demanded by USTR for pharmaceutical pricing programs abroad, but is not given in the Special 301 process that is used to make such demands.

The Special 301 adjudication process should be modified to provide for an appeal of legal, policy and factual determinations in the draft report to an independent body outside of the office of the USTR, e.g. to a body housed in the State Department’s office of general counsel or the Justice Department’s Office of Legal Counsel. For example, questions about interpretation of whether Special 301 violates the WTO agreement, international human rights obligations and the Doha Declaration involve important questions of international law that should not be determined by USTR itself.

3. Objective and Transparent Standards

As described in our analysis of the 2010 Report, the written decisions of the Agency are very difficult to interpret because they are incredibly vague. One of the marks of a non-arbitrary administrative process is that there are set standards being applied, which can then be appealed to the proper policy and legal authorities. But it is difficult to know what standards are being applied in many places in the Special 301 report because there are no citations to offending laws or policies, no quotation of them and no clear recitation of the specific standard being applied.

4. Public Interest Representation

Commercial industry has organized an entire association, IIPA, with great resources and with a major purpose being the participation in the adjudication process that results in Special 301 listing decisions. On the other side are foreign countries with no real influence in American politics and a diffuse range of public interest organizations, none of which receive any
foundation or member funding for participating in such adjudication. This is a recipe for corporate capture of administrative agencies.

To help global health organizations meaningfully participate in the process, participation grants should be established for NGOs to hire professional, legal and research assistance to participate in the process. Such grants are common, for example, in utility rate making determinations where utility companies have great interest and resources to participate but consumers tend to be diffuse and difficult to organize. In California, for example, non-profit organizations can receive the equivalent of attorney fees from the regulatory authority for meaningful participation in the proceedings on behalf of consumers. The Administration could also operate a small grant process that organizations could apply for collectively or individually.

5. Allowing Testimony Delivered via Teleconferencing or Web Conferencing

Last year, interested parties from overseas wished to testify at the hearing before the interagency committee chaired by USTR. Despite requests to accommodate them, no telephone, video, or web conferencing capabilities were used to allow this. It is important for committee members to hear from stakeholders affected by U.S. trade policy in order for them to understand the consequences of their actions. We therefore request that technological accommodations be made for the 2011 hearing to allow for testimony from those outside of Washington.

6. Inclusion of Relevant U.S. Government Agencies

The interagency committee that reviews submissions and other evidence to create the Special 301 Report should include wider representation from agencies whose work is affected by greater intellectual property protection of pharmaceutical products. DHHS staff was part of the committee in 2010, though no one from the agency participated in the public hearing. Other U.S.
government agencies work in the public health field, and could provide valuable input to the Special 301 process.

As mentioned above, PEPFAR enjoys substantial savings through the purchase of generic antiretrovirals, but faces rising costs in the near future as more patients require second line antiretrovirals (and improved first-line) antiretrovirals that are more likely to be protected by IP. The Food and Drug Administration should also be included in the Special 301 committee, because it has the expertise that trade officials and others lack concerning the safety of pharmaceuticals the best ways to address substandard health products.